Duopharma's share price weakness presents buying opportunity

KUALA LUMPUR: Investors may have been presented with a buying opportunity in Duopharma Biotech Bhd following the recent decline in its share price and resilient results in the first half of the year.

According to RHB Research, the pharmaceutical company's 1H21 core net profit was in line with expectations with a core net profit of RM33.5mil representing 45% and 49% of its and consensus full-year estimates.